Silver Spring, MD (STL.News) – The U.S. Food and Drug Administration (FDA) has approved Recarbrio (imipenem, cilastatin and relebactam), an antibacterial drug product to treat adults with Complicated Urinary Tract infections (cUTI) and complicated intra-abdominal infections (cIAI).

“The FDA remains focused on facilitating the development of safe and effective new antibacterial drugs to give patients more options to fight serious infections,” said Ed Cox, M.D., M.P.H., director for the Office of Antimicrobial Products in FDA’s Center for Drug Evaluation and Research.

Continue reading FDA approves new treatment for complicated urinary tract, complicated intra-abdominal infections at STL.News.